Press Releases AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2025-05-16 EDT			5-day change	1st Jan Change
184.02 ^USD	+1.29%		-0.31%	+3.56%

05-14	US FDA approves AbbVie's drug for a type of lung cancer	RE
05-14	US FDA approves AbbVie's drug for a type of lung cancer	RE

Press Releases

June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV	05-16	PR
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV	05-15	PR
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas	05-14	PR
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV	05-13	PR
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders	05-12	PR
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV	05-09	PR
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join - Contact The Gross Law Firm	05-08	PR
AbbVie to Present at the Bank of America Securities Healthcare Conference	05-06	PR
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV	05-06	PR
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm	05-05	PR
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV	05-02	PR
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"	05-01	PR
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV	05-01	PR
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)	04-29	PR
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV	04-29	PR
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV	04-28	PR
AbbVie: Q1 Earnings Snapshot	04-25	AQ
AbbVie Reports First-Quarter 2025 Financial Results	04-25	PR
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV	04-25	PR
AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines	04-24	PR
The Gross Law Firm Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV	04-24	PR
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders	04-22	PR
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV	04-21	PR
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More	04-18	PR
ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	04-17	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Press Releases

Filters